Management of onychomycosis: Examining the role of monotherapy and dual, triple, or quadruple therapies

Cutis

Volumn 74, Issue 1 SUPPL., 2004, Pages 5-9

  Gupta, Aditya K ^a,b   Lynch, Lindsay E ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; CICLOPIROX; GRISEOFULVIN; ITRACONAZOLE; KERATOLYTIC AGENT; TERBINAFINE;

ANTIFUNGAL ACTIVITY; CLINICAL TRIAL; DEBRIDEMENT; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; MONOTHERAPY; ONYCHOMYCOSIS; REVIEW; SURGICAL TECHNIQUE; TINEA PEDIS;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; HUMANS; ONYCHOMYCOSIS; UNITED STATES;

EID: 4143076893     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada - a multicenter survey of 2001 patients. Int J Dermatol. 1997;36:783-787.
2. Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43:641-648.
3. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol. 2000;43:244-248.
4. Turner RR, Testa MA. Measuring the impact of onychomycosis on patient quality of life. Qual Life Res. 2000;9:39-53.
5. Hay RJ. The future of onychomycosis therapy may involve a combination of approaches. Br J Dermatol. 2001;145:3-8.
6. Gupta AK. Fungus-free versus disease-free nails: reply [letter]. J Am Acad Dermatol. 2004;50:152.
7. Baran R, Hay RJ. New evidence for the efficacy of combination therapy in onychomycosis. Br J Dermatol. 2001;145(suppl):1.
8. Evans EG. The rationale for combination therapy. Br J Dermatol. 2001;145:9-13.
9. Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol. 2004;150:537-544.
10. Baran R, Hay RJ, Eckart H, et al. Onychomycosis: The Current Approach to Diagnosis and Therapy. London, England: Martin Dunitz Ltd; 1999.
11. Hettinger DF, Valinsky MS. Treatment of onychomycosis with nail avulsion and topical ketoconazole. J Am Podiatr Med Assoc. 1991;81:28-32.
12. Evans EG. Drug synergies and the potential for combination therapy in onychomycosis. Br J Dermatol. 2003;149:11-13.
13. Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol. 1992;17:44-49.
14. Gupta AK. Onychomycosis in the elderly. Drugs Aging. 2000;16:397-407.
15. Gupta AK, Ryder JE. How to improve cure rates for the management of onychomycosis. Dermatol Clin. 2003;21:499-505.
16. Hull PR. Onychomycosis - treatment, relapse and re-infection. Dermatology. 1997;194:7-9.
17. USP DI. Drug information for the Health Care Professional. Greenwood Village, Colo: Thompson Micromedex; 2003.
18. Penlac Nail Lacquer Topical Solution, 8% [package insert]. Berwyn, Pa: Aventis Pharmaceuticals Inc.; 2003.
19. Seebacher C. Action mechanisms of modern antifungal agents and resulting problems in the management of onychomycosis. Mycoses. 2003;46:506-510.
20. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43:S70-S80.
21. Gupta AK. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. J Am Acad Dermatol. 2000;43:S81-S95.
22. Sporanox [package insert]. Titusville, NJ: Janssen Pharmaceutica Products, LP; 2001.
23. Sigurgeirsson B, Olafsson JH, Steinsson JB, et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol. 2002;138:353-357.
24. Lamisil [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2001.
25. Gupta AK, Cooper E. Management of onychomycosis: combination therapy is not a new concept [abstract]. J Am Acad Dermatol. 2004;50:104.
26. Gupta AK, Konnikov N, Lynde C. Sequential pulse therapy with itraconazole and terbinafine to treat onychomycosis of the fingernails. J Dermatolog Treat. 2000;11:151-154.
27. Barchiesi F, Falconi DF, Scalise G. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob Agents Chemother. 1997;41:1812-1814.
28. Barchiesi F, Di Francesco LF, Compagnucci P, et al. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J Antimicrob Chemother. 1998;41:59-65.
29. Gupta AK, Kohli Y. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br J Dermatol. 2003;149:296-305.
30. Leyden JJ. Current issues in antimicrobial therapy for the treatment of acne. J Eur Acad Dermatol Venereol. 2001;15:51-55.
31. Gupta AK, Lynde CW, Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol. 2001;44:485-491.
32. Gupta AK. Efficacy and safety of combination therapy with itraconazole and terbinafine to treat dermatophyte toenail onychomycosis [abstract]. J Am Acad Dermatol. 2004;50:106.
33. Arenas R, Fernandez G, Dominguez L. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. Int J Dermatol. 1991;30:586-589.
34. Baran R, Feuilhade M, Combernale P, et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol. 2000;142:1177-1183.
35. Hay RJ, Clayton YM, Moore MK. A comparison of tioconazole 28% nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis. Clin Exp Dermatol. 1987;12:175-177.
36. Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. Br J Dermatol. 2001;145:21-26.
37. Rigopoulos D, Katoulis AC, Ioannides D, et al. A randomized trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis. Br J Dermatol. 2003;149:151-156.
38. Gupta AK. Evaluation of the mycological cure rates when ciclopirox nail lacquer is used in combination with oral terbinafine to treat toenail onychomycosis - six month interim results [abstract]. J Am Acad Dermatol. 2004;50:104.
39. Baran R, De Doncker P. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Derm Venereol. 1996;76:82-83.
40. Dominguez-Cherit J, Teixeira F, Arenas R. Combined surgical and systemic treatment of onychomycosis. Br J Dermatol. 1999;140:778-780.
41. Goodfield M, Evans EGV. Combined treatment with surgery and short duration oral antifungal therapy in patients with limited dermatophyte toenail infection. J Dermatol Treat. 2000;11:259-262.
42. Bonifaz A, Guzman A, Garcia C, et al. Efficacy and safety of bifonazole urea in the two-phase treatment of onychomycosis. Int J Dermatol. 1995;34:500-503.
43. Friedman-Birnbaum R, Cohen A, Shemer A, et al. Treatment of onychomycosis: a randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin. Int J Dermatol. 1997;36:67-69.
44. Hardjoko FS, Widyanto S, Singgih I, et al. Treatment of onychomycosis with a bifonazole-urea combination. Mycoses. 1990;33:167-171.
45. Rollman O. Treatment of onychomycosis by partial nail avulsion and topical miconazole. Dermatologica. 1982;165:54-61.
46. Rollman O, Johansson S. Hendersonula toruloidea infection: successful response of onychomycosis to nail avulsion and topical ciclopiroxolamine. Acta Derm Venereol. 1987;67:506-510.
47. Syed TA, Ahmadpour OA, Ahmad SA, et al. Management of toenail onychomycosis with 2% butenafine and 20% urea cream: a placebo-controlled, double-blind study. J Dermatol. 1998;25:648-652.
48. Torres-Rodriguez JM, Madrenys N, Nicolas MC. Non-traumatic topical treatment of onychomycosis with urea associated with bifonazole. Mycoses. 1991;34:499-504.
49. Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol. 2000;42:217-224.
50. Moncada B, Loredo CE, Isordia E. Treatment of onychomycosis with ketoconazole and nonsurgical avulsion of the affected nail. Cutis. 1983;31:438-440.